A recent Epigen Biosciences Inc. patent describes ribosomal protein S6 kinase β (p70S6K) inhibitors reported to be useful for the treatment of diabetes, autism spectrum disorders, fibrosis, fragile X syndrome, liver diseases and nonalcoholic steatohepatitis (NASH).